02:33 , Jul 13, 2019 |  BioCentury  |  Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than...
02:20 , Jan 18, 2019 |  BC Innovations  |  Targets & Mechanisms

Exploring 3-D genomic white space

Gene regulation is offering a new class of targets that operate on a higher level than DNA sequences and epigenetic markers: 3-D genomic structures. While strategies to drug the 3-D genome are still in their...
22:15 , Oct 3, 2018 |  BC Extra  |  Company News

MSKCC President & CEO resigns from Merck's board

President and CEO of Memorial Sloan Kettering Cancer Center Craig Thompson will immediately resign from the boards of Merck & Co. Inc. (NYSE:MRK) and Charles River Laboratories International Inc. (NYSE:CRL) following revelations of financial ties...
16:36 , Sep 21, 2018 |  BC Week In Review  |  Company News

Diagnostic companies Cancer Genetics, NovellusDx merging

Cancer diagnostic company Cancer Genetics Inc. (NASDAQ:CGIX) will merge with NovellusDx Ltd. (Jerusalem, Israel). NovellusDx shareholders will have a 49% equity stake in the company, which will retain Cancer Genetics’ name. NovellusDx’s assays distinguish passenger...
15:26 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

Grail reports first data from CCGA study

Grail Inc. (Menlo Park, Calif.) reported initial data from a lung cancer substudy of its observational Circulating Cell-Free Genome Atlas (CCGA) study, which aims to create a detailed atlas of cancer genetics. Data were presented...
11:55 , Jun 2, 2018 |  BC Extra  |  Clinical News

Grail reports first data from CCGA study

Grail Inc. (Menlo Park, Calif.) reported initial data from a lung cancer substudy of its observational Circulating Cell-Free Genome Atlas (CCGA) study, which aims to create a detailed atlas of cancer genetics. Data were presented...
17:52 , Jun 1, 2018 |  BC Week In Review  |  Financial News

Chinese investors lead Grail's $300M series C

Cancer detection company Grail Inc. (Menlo Park, Calif.) raised $300 million in an oversubscribed series C round on May 21. Ally Bridge Group, Hillhouse Capital and 6 Dimensions Capital led the round, with participation from...
17:40 , May 25, 2018 |  BioCentury  |  Finance

Grail’s Asia incentives

In light of Grail Inc.’s $300 million series C round from Chinese investors, the cancer detection company has several reasons to pursue a Hong Kong listing that go beyond high valuations. The series C round,...
00:12 , May 22, 2018 |  BC Extra  |  Financial News

Chinese investors lead Grail's $300M series C

Cancer detection company Grail Inc. (Menlo Park, Calif.) raised $300 million in an oversubscribed series C round late Monday. The company said the round was led by Ally Bridge Group and co-led by Hillhouse Capital...
19:25 , Feb 28, 2018 |  BC Extra  |  Financial News

Grail declines comment on Hong Kong IPO plans

Grail Inc. (Menlo Park, Calif.) declined to comment to BioCentury on a media report that said the company plans to raise up to $500 million in an IPO in Hong Kong. The report, published by...